Preventing amyloid formation by catching unfolded transmembrane segments.
A subset of protein misfolding diseases, including, for example, Alzheimer's disease, is associated with the formation of highly insoluble amyloid fibrils with a beta-sheet structure. The amyloidogenic human lung surfactant protein C (SP-C) is generated from SP-C precursor, which has a C-terminal domain (CTC) that prevents SP-C amyloid fibril formation. Analysis of the substrate specificity of CTC reveals that it binds to all amino acid residues that promote membrane insertion, provided that they are in a nonhelical conformation. In line with this unexpectedly general substrate specificity, the anti-amyloid function of CTC extends to a transmembrane segment other than that of (pro)SP-C, namely, the amyloid beta-peptide associated with Alzheimer's disease. These findings indicate that CTC is the first known chaperone to be directed towards nonhelical transmembrane segments and that it may be employed for the development of new diagnostics or anti-amyloid therapies.
Department of Anatomy, Physiology, and Biochemistry, SLU, The Biomedical Center, 75123 Uppsala, Sweden.
H
H
Johansson
C
C
Nerelius
K
K
Nordling
J
J
Johansson
D000682:Amyloid / Q000737:chemistry*; D000686:Amyloidosis / Q000517:prevention & control; D006801:Humans; D008565:Membrane Proteins / Q000737:chemistry; D018832:Molecular Chaperones / Q000737:chemistry; D017510:Protein Folding; D017433:Protein Structure, Secondary; D037721:Pulmonary Surfactant-Associated Protein C / Q000737:chemistry*; D013379:Substrate Specificity
D000682:Amyloid; D008565:Membrane Proteins; D018832:Molecular Chaperones; D037721:Pulmonary Surfactant-Associated Protein C